Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Amazon Explores AI Content Marketplace With Media Publishers 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
CARLSBAD, Calif., Feb. 21, 2018 -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will release fourth quarter and full year 2017 financial results after the close of trading on Wednesday, February 28, 2018. The Company's management team will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET to discuss the financial results and recent business developments.
Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 7067009. To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.
The call will be archived until Thursday March 15, 2018. The audio archive can be accessed by calling (855) 859-2056 in the U.S. or (404) 537-3406 from outside the U.S. The passcode for the audio replay is 70677009.
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Investor Relations Contact
Lynn Pieper
(415) 937-5402
[email protected]
